GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT04115748
- Locations
- 🇭🇺
Synexus (DRS) - Synexus Magyarorszag Kft. Budapest, Budapest, Hungary
🇵🇱Centrum Medyczne Pratia Gdynia, Gdynia, Poland
🇵🇱Medycyna Kliniczna Marzena Waszczak-Jeka, Warszawa, Poland
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 37
- Registration Number
- NCT04112303
- Locations
- 🇯🇵
Fukui-ken Saiseikai Hospital, Fukui, Japan
🇯🇵Chiba University Hospital, Chiba, Japan
🇯🇵Iizuka Hospital, Iizuka, Japan
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
- Conditions
- Compensated CirrhosisPrimary Sclerosing Cholangitis
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT04060147
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California San Francisco, Liver Clinic, San Francisco, California, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT04049617
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, LLC, Christchurch, New Zealand
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇳🇿Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
- Conditions
- Diabetic Kidney Disease
- Interventions
- Drug: SELDrug: Placebo
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 384
- Registration Number
- NCT04026165
- Locations
- 🇺🇸
North Shore University Hospital: Division of Nephrology, Great Neck, New York, United States
🇺🇸Knoxville Kidney Center, PLLC, Knoxville, Tennessee, United States
🇺🇸Research By Design, LLC, Chicago, Illinois, United States
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Drug: Placebo to match Seladelpar
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1
- Registration Number
- NCT04024813
- Locations
- 🇺🇸
University of Colorado Denver and Hospital, Aurora, Colorado, United States
🇺🇸Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco, California, United States
🇺🇸Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
- Conditions
- HIV-1-infection
- Interventions
- Other: B/F/TAF
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT04009057
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Kaplan Medical Center, Rehovot, Israel
🇮🇱Tel Aviv Souraski Medical Center, Tel Aviv, Israel
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 109
- Registration Number
- NCT03987074
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Quality Medical Research, PLLC, Nashville, Tennessee, United States
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- Conditions
- Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 227
- Registration Number
- NCT03964727
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Arizona Oncology Associates PC-HAL, Goodyear, Arizona, United States
🇦🇺Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAF
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 62
- Registration Number
- NCT03960645
- Locations
- 🇩🇴
Instituto Dominicano de Estudios Virologics (IDEV), Santo Domingo, Dominican Republic
🇹🇭Thai Red Cross AIDS Research Centre, Pathumwan, Thailand
🇹🇭Faculty of Medicine-Khon Kaen University, Khon Kaen, Thailand